unknown
Stage
About
Audion Therapeutics BV is a clinical-stage biotechnology company developing drug therapies to treat acquired sensorineural hearing loss by targeting the gamma-secretase protein complex; its lead candidate (LY3056480) has been administered intratympanically and evaluated in Phase I/IIa studies. The company focuses on small-molecule gamma-secretase inhibitors to restore cochlear hair cell function and improve hearing.
Explore Audion Therapeutics's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.